ReviewGene therapy2026
Antimicrobial resistance and gene therapy: emerging molecular strategies for a global health threat.
Review in Gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is one of the most serious and pressing health challenges facing modern medicine. Despite advances in antimicrobial stewardship, diagnostics and infection prevention, the rapid emergence and spread of resistant pathogens continues to limit treatment options and increase morbidity, mortality and healthcare costs. The discovery of new innovative antimicrobial therapies remains of paramount importance. In this context, gene therapy is gaining attention as a complementary strategy that can directly target the molecular genetic determinants of antimicrobial resistance. Recent advances in RNA-based technologies and CRISPR-Cas systems have enabled increasingly precise manipulation of microbial genomes, opening up the possibility of restoring antimicrobial susceptibility, reducing virulence and limiting the spread of resistance genes.
Indexed as
Identifiers
41974871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.